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Individuals with congenital disorder of glycosylation type
Ia (CDG-Ia) have a multisystem disorder that is caused by
defects in protein glycosylation due to reduced activity of
the phosphomannomutase 2 enzyme (PMM2). The fact
that there is residual enzyme activity in these patients
generated the idea that excess amounts of the enzyme’s
substrate, mannose-6-phosphate, could be used to coax
additional activity out of the enzyme and perhaps improve
outcomes in these patients. Unfortunately, trials of man-
nose supplementation in patients with CDG-Ia have not
been successful. Recent data suggest this supplementation
was too late because it missed a critical role for protein
glycosylation during embryonic development. Schneider
et al. created a mouse model with reduced Pmm2 activity
that was embryonic lethal. When the pregnant mothers
of these pups were provided oral mannose in their drink-
ing water, lethality was rescued and the resulting pups
appear to be developmentally normal. Because the pups
thrive after the mannose supplementation is removed, it
appears that embryonic development is a crucial time for
protein glycosylation and that future human trials should
be considered in mothers at high risk of having a child
with CDG-Ia.
Schneider et al. Nature Medicine 18: 71–73.Off and On
Although Angelman syndrome is caused by loss-of-
function mutations of UBE3A, affected individuals do
possess a normal copy of the gene, albeit one that is
silenced due to imprinting. This provides an intriguing
approach to treatment for this disorder: can the normally
silenced paternal copy of UBE3A be switched back on to
rescue the neurological deficits associated with this
disorder? Huang et al. developed a clever screen to iden-
tify compounds that could do just that. They created
a knockin mouse that had a paternal Ube3a allele that
was fused with the gene for a fluorescent protein. Com-
pounds that turn this allele on could be detected via fluo-
rescence in cultured neurons. The key hit in their screen
was a topoisomerase I inhibitor—and other compounds
of this class also switch on the paternal allele. The most
potent compound, topotecan, is an FDA-approved drug
that yields active, wild-type levels of UBE3A in cul-
tured neurons, albeit through an unknown mechanism.1Department of Human Genetics, Emory University School of Medicine, Atlan
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The AmericaAlthough the drug is not long-lived in mice, its effect on
Ube3a expression lasts at least several weeks beyond
the drug, suggesting it could be feasible to study the
effects of restoration of Ube3a expression on Angelman
syndrome phenotypes.
Huang et al. Nature 481: 185–189.
Forced Tolerance
Although not a cure, enzyme replacement therapy (ERT)
prolongs life and improves the disease course of individ-
uals with infantile Pompe disease. However, patients
with no detectable acid a-glucosidase (GAA) protein,
who are otherwise known as CRIM (cross-reacting im-
munological material)-negative, eventually develop anti-
bodies to the recombinant enzyme, thereby limiting the
effectiveness of the therapy and yielding poor prognosis.
To circumvent this problem, Messinger et al. attempted
to induce immune tolerance in CRIM-negative patients
with infantile Pompe disease. Two patients were treated
with an immune tolerizing regimen after anti-GAA anti-
bodies developed; another two CRIM-negative patients
were treated with an immune tolerizing regimen prophy-
lactically at the onset of ERT. All four patients are now
tolerant to ERT despite being off the immune tolerance
regiment, and they range in age from 18 to 56 months,
which is longer than the typical life expectancy for in-
fantile Pompe disease. They also generally show a better
response to ERT than would be expected for CRIM-
negative patients, and none is completely ventilator-
dependent. This research group is recruiting additional
patients with Pompe disease for a clinical trial of this toler-
izing regimen, and this same type of approach might also
be useful for other genetic conditions treated with ERT.
Messinger et al. Genetics in Medicine 14: 135–142.
If You Can’t Stand the Heat
Especially here in the South, where it is hot and humid,
a handful of young athletes die unexpectedly each summer
when football training begins. Why does this happen
when hundreds of other boys play without incident?
Data suggest that certain people are genetically predis-
posed to be more sensitive toward exertion and heat.
One of the genes that has been implicated in this sensi-
tivity is the gene for the type I ryanodine receptor
(RYR1). RYR1 mutation is also a cause of malignantta, GA 30322, USA
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hyperthermia, which is a life-threatening reaction to
certain volatile anesthetics in which there is essentially
out-of-control metabolism in skeletal muscle. Other than
telling individuals who carry an RYR1 mutation to sit out
sports or to avoid surgery, what can be done? Lanner
et al. recently identified a drug that prevents heat-induced
sudden death in a mouse model with a knockin mutation
in Ryr1. In the absence of the drug, these mice die of a heat-
stroke-like condition within minutes at 37C. This drug
activates the master metabolism regulator, AMP-activated
protein kinase (AMPK), but it turns out that this is not
the mechanism by which the drug protects the mice
against heat. Instead, it influences calcium leak from the
sarcoplasmic reticulum in muscle, which is the initiator
of a downward spiral toward muscle contraction, break-
down of the muscle fibers, and ultimately death. So, not
only does this work increase our understanding of the
mechanism by which this extreme response to heat occurs,
it also provides a candidate drug for prophylaxis in
individuals prone to this heat response because of RYR1
mutations.
Lanner et al. Nature Medicine. Published online January 8,
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Although zebrafish are a popular model system and their
reference genome is available, we don’t actually have a
good understanding of the structural genetic variation in
this species. To remedy this, Brown et al. recently per-
formed array comparative genomic hybridization on fish
from three laboratories and one native strain of zebrafish.
They uncovered extensive copy-number variation that
encompassed four times more of the zebrafish genome
than does structural variation in other vertebrate genomes
examined thus far. Even this is an underestimate because
their array design avoided areas with segmental duplica-
tions, which are known to generate and flank copy-
number variants. A minority of the variable elements
they uncovered are found in all four groups of fish exam-
ined, and this is dwarfed by the strain-specific elements,
which are almost ten times more common. Expression
analyses demonstrate that at least some of these elements
are correlated with changes in gene expression and there-
fore could affect phenotype. Zebrafish users beware; their
similar appearance belies extensive underlying genomic
variation.
Brown et al. PNAS 109: 529–534.This Month in Our Sister JournalsVariant Inference in Isolated Populations
Individuals that comprise an isolated population are
more likely to share regions of the genome identity by
descent (IBD). Thus, if you sequence one genome, you
can infer the sequence variation in those individuals
that share segments of the genome IBD. This is no
different than haplotype inference in outbred popula-
tions, but use of isolated populations gives you more
bang for your limited sequencing bucks. Gusev et al.
make use of this approach in a sample they have studied
from the Pacific Island of Kosrae. They have recruited
almost all the adult population of the island in order
to identify genes that contribute to Mendelian and
complex traits, and they have genotyped each of them
by using SNP arrays. In a recent study in Genetics, Gusev
et al. developed a method to select individuals forgenome sequencing such that they could maximize the
amount of information that could be inferred from the
SNP genotypes in the population as a whole. Compared
to random selection of individuals for genome
sequencing, this method allows them to impute the
same fraction of the sequence variants in the population
with significantly fewer sequenced individuals. Because
they impute variation on the basis of the genome
sequence from the population itself, they can infer varia-
tion that is otherwise rare in the human population, even
in neighboring Korean populations. These rare variants
could hold the key to the high prevalence of obesity
and other metabolic disorders in this population, which
has so far gone largely unexplained by common genetic
variation.
Gusev et al. Genetics 190: 1–11.10, 2012
